Latest Content

FDA approved Cavhanza, a new nilotinib formulation for adults with Ph+ CML that may offer more flexible dosing and easier administration.

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic triple-negative breast cancer.

A Lynch syndrome survivor shares essential prep tips, the importance of stomach cancer screening and how a mindset shift beats yearly scanxiety.

In a phase 3 study, Opdivo plus Yervoy did not improve overall survival when combined with chemotherapy for HER2-negative gastric or GEJ cancer.

Dr. John Marshall explains why biomarker testing should be done early in colorectal cancer to guide treatment and identify targeted therapies.

Kassiane Saieed explains how genomic tools provide data to help patients personalize their breast cancer treatment and survivorship.

Exercise after colon cancer chemotherapy reduced recurrence risk, improved survival and quality of life, according to the CHALLENGE trial.

Triage Cancer's Beyond Diagnosis program provides free webinars, guidance, and support for parents living with metastatic cancer.

I thought I understood breast cancer, until a routine conversation at the pharmacy changed everything.

A blood cancer survivor debunks the movie myth of a quick cure, exposing the harsh, lasting side effects that remain after ringing the bell.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer.

Giredestrant plus Afinitor may help patients with metastatic breast cancer delay chemotherapy and stay on effective treatment longer.